Full-Time

IT Engineer III Senior Manager

Field Reporting

Posted on 5/9/2026

 Otsuka Pharmaceutical

Otsuka Pharmaceutical

1,001-5,000 employees

Global pharmaceutical company developing medicines

Compensation Overview

$150k - $224.3k/yr

+ Incentive Opportunity

Princeton, NJ, USA

In Person

Category
IT & Security (1)
Required Skills
Datadog
Power BI
Microsoft Azure
Agile
ServiceNow
SQL
AWS
New Relic
Confluence
Splunk
Data Analysis
Requirements
  • Data Analysis and Visualization: Understanding how to analyze data and create meaningful visualizations is crucial. This includes knowledge of different types of charts and graphs and when to use them.
  • Power BI Desktop: Proficiency in using Power BI Desktop to create reports and dashboards. This includes understanding how to import data, create data models, and use DAX (Data Analysis Expressions) for calculations.
  • Data Modeling: Ability to design and implement data models that are efficient and scalable. This includes understanding relationships, hierarchies, and data normalization.
  • DAX (Data Analysis Expressions): Strong skills in DAX are necessary for creating complex calculations and measures within Power BI.
  • Power Query: Knowledge of Power Query for data transformation and cleaning. This involves using M language to manipulate data before it is loaded into the Power BI model.
  • SQL: Proficiency in SQL for querying databases and extracting data. This is important for integrating data from various sources into Power BI.
  • Understanding of Business Intelligence (BI) Concepts: A solid understanding of BI concepts and how Power BI fits into the broader BI landscape.
  • Data Warehousing: Familiarity with data warehousing concepts and technologies, as Power BI often interacts with data warehouses.
  • Cloud Services: Knowledge of cloud services, particularly Microsoft Azure, as Power BI is often used in conjunction with Azure services.
  • Communication and Collaboration: Strong communication skills to work with stakeholders and understand their requirements. Collaboration skills are also important for working with teams.
  • Problem-Solving: Ability to troubleshoot issues and optimize Power BI solutions for performance and usability.
  • Security and Governance: Understanding of data security and governance practices to ensure data is protected and compliant with regulations.
Responsibilities
  • Work with the Solution Architect to translate business and functional requirements into well-architected technical solutions.
  • Manages the design and implementation of solutions that align with Otsuka’s enterprise architecture, data strategy, and security standards.
  • Develop and configure systems across cloud (AWS, Azure), on-premises, and hybrid environments.
  • Build automation scripts and reusable components to streamline deployments.
  • Participate in code reviews, configuration management, and version control practices.
  • Validate scalability, performance, and fault-tolerance of deployed systems.
  • Collaborate with platform lead, product owner, business analysts, architects, and QA teams to ensure alignment with project goals.
  • Work within Agile/Scrum or hybrid delivery frameworks to support iterative releases.
  • Manage to technical deliverables and contribute to project documentation, timelines, and risk assessments.
  • Coordinate with external vendors, managed service providers, and internal support teams.
  • Provide clear, concise technical input in planning and status meetings.
  • Maintain high availability of systems through proactive monitoring and issue resolution.
  • Analyze incidents, perform root-cause analyses, and implement preventive measures.
  • Apply observability tools (e.g. Splunk, Datadog, New Relic) for performance management.
  • Automate infrastructure provisioning, deployment pipelines, and alerting systems to reduce manual interventions.
  • Develop operational runbooks and participate in on-call rotations as needed.
  • Contribute to disaster-recovery testing and business continuity planning.
  • Ensure solutions comply with Otsuka’s cybersecurity, GxP, data-privacy, and regulatory requirements (e.g., GDPR, HIPAA).
  • Implement and enforce policies for identity and access management, encryption, and network security.
  • Participate in internal and external audits, ensuring systems meet required documentation and traceability.
  • Contribute to change control, configuration management, and vulnerability remediation activities.
  • Evaluate emerging technologies—cloud services, DevOps tooling, AI frameworks, and automation platforms—and recommend adoption strategies.
  • Manage proofs of concept (POCs) and pilot deployments for new tools or patterns.
  • Collaborate on FinOps and cost-optimization initiatives to enhance efficiency.
  • Promote standardization and reusability across platforms, applications, and processes.
  • Share best practices through documentation, mentoring, and internal community engagement.
  • Maintain detailed records of configurations, workflows, and system changes in Otsuka’s knowledge base (e.g., Confluence, ServiceNow).
  • Create and maintain architectural diagrams, data flow documentation, and SOPs.
  • Support training sessions or handovers to ensure continuity and operational readiness.
 Otsuka Pharmaceutical

Otsuka Pharmaceutical

View

Otsuka Pharmaceutical is a global health-focused company that develops and markets medicines and nutraceutical products. It creates pharmaceuticals like Abilify (aripiprazole), an antipsychotic, and consumer health brands such as Pocari Sweat, an ion-replacement drink. Its products work by medical mechanisms (Abilify modulates dopamine and serotonin receptors to treat psychiatric conditions) and by supporting hydration and electrolyte balance (Pocari Sweat). Otsuka differentiates itself through a long, international growth path from its roots as a Japanese chemical manufacturer, a balanced portfolio spanning prescription drugs and health beverages, and a philosophy of developing new products to improve health worldwide. Its goal is to deliver healthier outcomes for people around the world by expanding access to innovative medicines and health-related consumer products.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

Tokyo, Japan

Founded

1921

Simplify Jobs

Simplify's Take

What believers are saying

  • Voyxact achieves 82.5% hematuria improvement in IgAN trial at 48 weeks.
  • Acquired Transcend Therapeutics for $700M to advance psychiatric MDMA analog.
  • Partnered Keio University on May 8, 2025, for psychedelics infrastructure.

What critics are saying

  • AbbVie acquires Gilgamesh bretisilocin for $1.2B, leapfrogging Otsuka psychedelics.
  • Voyxact confirmatory trial fails kidney preservation in 18-24 months.
  • Japanese regulations block psychedelics trials in 24-36 months.

What makes Otsuka Pharmaceutical unique

  • Pioneered IV solutions in 1946, becoming Japan's top supplier.
  • Launched Pocari Sweat ion drink and Abilify antipsychotic globally.
  • Focuses on carbostyril-based original drugs since 1980.

Help us improve and share your feedback! Did you find this helpful?

Your Connections

People at Otsuka Pharmaceutical who can refer or advise you

Benefits

Health Insurance

Dental Insurance

Vision Insurance

401(k) Company Match

Tuition Reimbursement

Student Loan Assistance

Paid Holidays

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

0%
Dealroom.co
Mar 27th, 2026
Transcend Therapeutics company information, funding & investors

Transcend Therapeutics, developing the next generation of psychoactive compounds for neuropsychiatry focused on patient access. Here you'll find information about their funding, investors and team.

Fierce Biotech
Mar 27th, 2026
Otsuka buys Transcend Therapeutics for $700M upfront in psychiatric drugs deal

Otsuka Pharmaceutical has acquired Transcend Therapeutics for $700 million upfront through its subsidiary Otsuka America, with potential milestone payments of up to $525 million. The deal gives Otsuka access to Transcend's MDMA analogue for psychiatric conditions currently in development.

The Associated Press
Mar 25th, 2026
Otsuka's Voyxact shows 82.5% hematuria improvement in IgA nephropathy trial at 48 weeks

Otsuka presented new Phase 3 VISIONARY trial data for VOYXACT (sibeprenlimab-szsi) in IgA nephropathy patients at the 2026 ISN World Congress of Nephrology. The analyses showed 82.5% of patients receiving sibeprenlimab achieved negative microscopic hematuria at week 48, compared with 52.6% on placebo. Median time to achieve hematuria negativity was nine weeks versus 24 weeks for placebo. VOYXACT, approved under accelerated approval in the US, is a monoclonal antibody that inhibits APRIL, a key driver in IgAN pathogenesis. Previously reported data showed the drug met its primary endpoint with a 51.2% placebo-adjusted reduction in proteinuria at nine months. The trial continues evaluating sibeprenlimab's effect on preserving kidney function over 24 months.

Business Wire
Mar 2nd, 2026
Paradise ultrasound renal denervation system now covered by insurance in Japan for resistant hypertension

Otsuka Medical Devices and Otsuka Pharmaceutical have launched the Paradise Ultrasound Renal Denervation system in Japan, with National Health Insurance coverage effective 1 March. The device, developed by US subsidiary Recor Medical, treats resistant hypertension by reducing sympathetic nerve overactivity surrounding renal arteries. The system targets patients whose blood pressure remains above target despite using three different antihypertensive medications, including a diuretic. This marks Japan's first ultrasound renal denervation treatment. The Paradise system received FDA approval in the US in November 2023. Under a co-promotion agreement, both Otsuka companies will leverage their cardiovascular and renal expertise to deliver the treatment according to guidelines established by Japanese medical societies. The system offers a new option for resistant hypertension patients at high risk of serious cardiovascular complications.

The Associated Press
Feb 6th, 2026
Sky Labs secures exclusive deal with Otsuka Pharmaceutical to launch ring-type blood pressure monitor in Japan

Sky Labs has signed an exclusive distribution agreement with Otsuka Pharmaceutical to launch its ring-type blood pressure monitor, CART BP pro, in Japan's hospital and clinic market. The deal follows an MoU signed in December 2024. CART BP pro uses photoplethysmography technology to measure blood pressure without a cuff, allowing comfortable monitoring during daily activities and sleep. The device has already achieved success in South Korea, with over 150,000 prescriptions across 1,700 medical institutions since its 2023 approval and national health insurance coverage in 2024. Japan's hypertension market includes approximately 43 million patients, with 29% failing to achieve blood pressure control and 33% unaware of their condition. Sky Labs will leverage Otsuka's distribution network and cardiovascular expertise to expand across Japanese healthcare facilities.